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Background: Angiogenesis plays an essential role in tumor growth and metastasis, and is a major target in cancer
therapy. VEGFR and PDGFR are key players involved in this process. The purpose of this study was to assess the
incidence of genetic variants in these receptors and its potential clinical implications in colorectal cancer (CRC).
Methods: VEGFR2, PDGFRα and PDGFRβ mutations were evaluated by sequencing their tyrosine kinase domains
in 8 CRC cell lines and in 92 samples of patients with CRC. Correlations with clinicopathological features and
survival were analyzed.
Results: Four SNPs were identified, three in PDGFRα [exon 12 (A12): c.1701A>G; exon 13 (A13): c.1809G>A; and
exon 17 (A17): c.2439+58C>A] and one in PDGFRβ [exon 19 (B19): c.2601A>G]. SNP B19, identified in 58% of tumor
samples and in 4 cell lines (LS174T, LS180, SW48, COLO205), was associated with higher PDGFR and pPDGFR
protein levels. Consistent with this observation, 5-year survival was greater for patients with PDGFR B19 wild type
tumors (AA) than for those harboring the G-allele genotype (GA or GG) (51% vs 17%; p=0.073). Multivariate analysis
confirmed SNP B19 (p=0.029) was a significant prognostic factor for survival, independent of age (p=0.060) or TNM
stage (p<0.001).
Conclusions: PDGFRβ exon 19 c.2601A>G SNP is commonly encountered in CRC patients and is associated with
increased pathway activation and poorer survival. Implications regarding its potential influence in response to
PDGFR-targeted agents remain to be elucidated.
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Colorectal cancer (CRC) is the third most common
tumour in the world, with over 1.2 million new cases
diagnosed every year, and is responsible for about 8% of
cancer related deaths [1]. Approximately one third of
patients present metastatic disease at diagnosis, and
about 40% of those with early-stage tumors will eventu-
ally relapse at some point over the course of the disease
[2,3]. Although prognosis has greatly improved over the* Correspondence: rgcarbonero@hotmail.com
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distribution, and reproduction in any mediumpast decades due to significant surgical and medical
advances, once the tumor has progressed beyond surgi-
cal resectability, the disease is essentially incurable and
median survival ranges from 14 to 24 months with best
available systemic therapy [4]. Development of new
more effective agents is thus actively pursued.
Angiogenesis has become a major target in colorectal
cancer therapy. Bevacizumab, a humanized monoclonal
antibody against the vascular endothelial growth factor
A (VEGF-A), was the first antiangiogenic agent to dem-
onstrate efficacy in CRC. In the pivotal study by Hurwitz
et al., the addition of this agent to irinotecan-based com-
bination cytotoxic therapy significantly improved sur-
vival compared to irinotecan-based chemotherapy aloneCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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zumab has been tested in combination with other chemo-
therapy regimens with more modest results [3,4]. More
recently, a benefit in survival has been also reported in
patients with advanced CRC with two new promising
antiangiogenic drugs: aflibercept (a VEGF trap) in com-
bination with FOLFIRI (folinic acid, 5-fluoruracil and
irinotecan) following progression to oxaliplatin-based
therapy [6], and regorafenib (a novel tyrosine kinase in-
hibitor targeting VEGFR, PDGFR, FGFR, RET, KIT and
TIE2) as single-agent therapy in patients who had pro-
gressed to all standard therapies [7]. These results clearly
illustrate angiogenesis inhibition is to play a major role in
the management of this disease.
Angiogenesis is a highly controlled process under
physiological conditions, such as embryonal develop-
ment, postnatal growth and wound healing, but is also a
critical driver of tumor growth and progression [8]. It is
tightly regulated by a complex equilibrium among differ-
ent pro- and antiangiogenic factors secreted both by
tumor cells and by cells of the tumor microenvironment
(pericytes, endothelial, mesenchymal or immune cells).
VEGF and their receptors represent one of the best vali-
dated pathways involved in angiogenesis [9,10]. VEGF
stimulates both proliferation and migration of endothe-
lial cells, enhances microvascular permeability, and is
essential for revascularization during tumor formation.
It is commonly over-expressed in human tumors, and this
is often associated with increased vascular density and
more aggressive clinical behavior. VEGF-A and its main
receptor, VEGFR2/KDR, are key members of this family
and common targets of antiangiogenic agents [11,12].
Platelet-derived growth factor (PDGF) and their recep-
tors (PDGFR-α, PDGFR-β and PDGFR-αβ) play also a
critical role in angiogenesis regulation by exerting
important control functions in mesenchymal cells during
development [13]. PDGF is expressed by endothelial
cells and acts in a paracrine manner by recruiting
PDGFR-expressing cells, such as pericytes and smooth
muscle cells, to the developing vessels, thus improving
pericyte coverage and vessel function. PDGF signaling
promotes cell migration, survival and proliferation and
indirectly regulates angiogenesis by inducing VEGF tran-
scription and secretion [10,13,14]. Mutations involving
up-regulation of PDGF and/or PDGFR, as well as
PDGFR-dependent growth stimulation, have been docu-
mented in a number of solid tumors and hematological
malignancies, suggesting a likely role of this pathway in
carcinogenesis [10,15]. Moreover, agents antagonizing
PDGFR-mediated signaling have also demonstrated
antineoplastic activity in preclinical models and in clin-
ical trials, including some conducted in patients with
CRC (i.e. regorafenib) [7]. Nevertheless, several other
drugs also targeting these pathways (i.e. sunitinib,sorafenib) [16,17] have failed to prove a significant posi-
tive impact on the outcome of patients with CRC. The
biological grounds for these discordant results are not
well understood.
Therefore, and in spite of their undeniable success,
only a small proportion of patients do actually benefit
from antiangiogenic agents, and reliable tools to pro-
spectively identify which patients are more likely to
benefit are scarce. In this scenario, efforts to unravel the
intricate molecular pathways governing tumor angiogen-
esis are certainly needed for progress to be made. In the
present study, we sought to evaluate the incidence of
genetic polymorphisms of some of the key players of
angiogenesis, such as VEGFR-2, PDGFR-α and PDGFR-
β, and their potential influence in CRC biology. With
this purpose we sequenced the tyrosine kinase domains
of these receptors in 8 CRC cell lines (T84, LOVO,
LS174T, HT29, LS180, SW48, SW480, COLO205) and
in 92 tumor samples of patients with colorectal adeno-
carcinoma. Correlations of encountered genetic variables
with protein expression in cell lines, as well as with clin-
icopathological features and survival of these patients
were also analyzed to assess their potential biological
and clinical implications.
Methods
Laboratory procedures
CRC cell lines
Eight human CRC cell lines (T84, LOVO, LS174T, HT
29, LS180, SW48, SW480 and COLO205) were selected
and purchased from the European Collection of Cell
Cultures (ECACC). They were representative of patients
with different gender, age and tumor stage.
Cell culture
Each cell line was grown in conditions of temperature,
humidity, O2 and CO2 levels, culture medium and sup-
plements according to providers’ instructions. Once they
reached confluence in monolayer DNA extraction was
performed. The total DNA yield was determined using a
Nanodrop ND-1000 spectrophotometer (Nanodrop
Tech, DE, USA).
DNA isolation from human tumor samples and culture cells
Formalin-fixed paraffin-embedded tissues from the
92 selected CRC patients were provided by the Path-
ology Departments of the corresponding institutions.
Samples were mainly obtained from the primary tumor
(96%), either by surgical (87%) or endoscopic proce-
dures. Three tissue sections of each tumor were first
deparaffinized and rehydrated by serial passes in D-
Limoneno (Histo-ClearW, National Diagnostic, Atlanta,
GA, USA) and ethanol (100%). Then, DNA isolation
from both human tumor tissue samples and culture cells
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extraction kit (Durviz, Valencia, Spain) according to the
manufacturer’s instructions and then purified using ion
exchange columns (QIAGEN Miniprep kit Cat. No.
27106). The total DNA yield was determined using a
Nanodrop ND-1000 spectrophotometer (Nanodrop
Tech, DE, USA).
Genotyping
Public databases including National Center for Biotech-
nology Information (NCBI) (http://www.ncbi.nlm.nih.
gov), University of California Santa Cruz (UCSC) Genome
Bioinformatics (http://genome.ucsc.edu) and Ensembl
Genome Browser (http://www.ensembl.org/index.html)
were reviewed to obtain the haplotypes of the three genes
of interest and their reported genetic variants. The exomic
regions corresponding to the tyrosine kinase domains,
which were the regions with the highest probability of
mutations, were then identified for each gene: exons 17
to 26 for VEGFR2, and exons 12 to 21 for PDGFRα
and PDGFRβ. Specific primers were designed to amplify
these exons using expert software in order to minimize
non-specific or erroneous amplifications and improve
outcomes. Primers used in this study are described in
Additional file 1: Table S1. Amplification of the tyrosine
kinase domains in both CRC cell lines and tissue samples
was performed by a polymerase chain reaction (PCR)
method. Fifty nanograms of the genomic purified DNA
were amplified in a PCR reaction containing 1.5 units of
DNA polymerase EuroTAQ (Genycell Biotech Spain SL;
Santa Fe, Granada, Spain), 1xEuroTaq buffer, 2.5 mM
Mg2+, 0.4 μM forward and reverse primers, 80 μM
dNTPs (20 μM each one), 1% DMSO and 1M betaine in
a volume of 50 μl. The PCR cycling conditions were
as follows: initial denaturation at 94°C for 5 minutes,
5 cycles at 94°C for 1 minute, and annealing that began
at 67°C for 45 seconds; this temperature was decreased
2°C each cycle to 59°C (67, 65, 63, 61, 59) and then
45 seconds at 72°C. This was followed by 35 cycles
at 95°C 1 minute, 55°C for 45 seconds and 72°C for
45 seconds. The last step was a final extension cycle at
72°C for 10 minutes.
DNA sequencing
PCR products were first purified using the microClean
kit (Microzone Ltd.; Haywards Heath, UK) or ExoSAP-
ITW for PCR Product Clean-Up USB (Affimetrix
Inc; Santa Clara, CA, USA) for individual reactions or
PERFORMAWDTV V396-Well Short Plates (Genycell
Biotech Spain SL; Santa Fe, Granada, Spain) for
96 plate reactions. Direct bidirectional sequencing of the
PCR products was done using BigDyeWTerminator
Cycle v3.1 Sequencing Kit (Applied Biosystems; Carlsbad,
CA, USA) and ABI 3110 Genetic Analyser (AppliedBiosystems) according to the manufacturer’s instructions.
All fragments were double-strand sequenced a number of
times, and genetic variations found were checked twice.
Sequencing analysis was performed using Chromas Lite,
Clustal W and DiAlign software.
Analysis of protein expression
Cells were washed twice in 1× PBS, pelleted for 30 sec-
onds at 14000× g and lysed in lysis buffer (Tris–HCl pH
7.5 50 mM, NP40 1%, glycerol 10%, NaCl 150mM,
complete protease inhibitor cocktail, 2 mM; Roche).
After centrifugation, supernatant protein extracts were
aliquoted and stored at −80°C until use. The amount of
protein was determined by Bradford assay using BSA
(bovine serum albumin) as a standard. The appropriate
protein quantity was dissolved in Laemli buffer (Tris–
HCl pH 6.8 62.5mM, glycerol 10%, SDS 1%, 2-mercapto
ethanol 5%, bromphenol blue 0.0025%) and the proteins
were separated in SDS-PAGE gels (12%) before they
were blotted onto Nitrocellulose Transfer membrane
(Whatman - Protrans). Primary antibodies employed
were: p-PDGFR-β (Tyr1021)-R 1:400 (Santa Cruz#sc-
12909-R), PDGFR-β 1:500 (Santa Cruz#sc-339), tubulin
1:10000 (Sigma – T6557). The secondary antibodies
used were goat anti-rabbit Alexa Fluor 680 1:5000
(Invitrogen – A21057) and donkey anti-mouse IRDye
800CW 1:5000 (Rockland Inc. – 605-731-002).
CRC study population, tumor samples and data collection
Patients that met the following inclusion criteria were
selected for the present study: (1) histologically con-
firmed diagnosis of primary CRC; (2) adequate clinical
data recorded in medical charts; (3) adequate tissue
specimen available for additional molecular assays
(a proportion of tumor cells > 50% was required). Cases
were reviewed according to a previously designed proto-
col which included the following clinical data: age, sex,
date of diagnosis, baseline carcinoembryonic antigen
(CEA) plasma levels, primary tumor location, TNM
stage [18], histological type, tumor differentiation, surgi-
cal treatment (type and outcome of surgery), chemother-
apy (adjuvant or for advanced disease, regimen used),
radiotherapy (neoadjuvant, adjuvant or palliative), date
of last visit or death and cause of death. The study
protocol was approved by the institutional review boards
of participating centers.
Main characteristics of the 92 included patients are
summarized in Table 1 and are representative of a stand-
ard CRC population. The median age was 68 years, 63%
were male and 40% presented advanced disease at diag-
nosis. The great majority had conventional adenocarcin-
omas (86%) and only 13% were poorly differentiated
tumors. Cancer specific therapy is outlined in Additional
file 1: Table S2. Patients with early stage disease (I-III)
Table 1 Population and tumor samples characteristics
N (%)
Age (years)
• Median (range) 68 (45–87)
Gender
• Female 34 (37.0%)
• Male 58 (63.0%)
Primary tumor location
• Right colon 27 (29.3%)
• Transverse colon 5 (5.4%)
• Left colon 9 (9.8%)
• Sigmoid colon 18 (19.6%)
• Recto sigmoid colon 14 (15.2%)
• Rectum 19 (20.7%)
Histology
• Conventional adenocarcinoma 79 (85.9%)
• Mucinous or colloid adenocarcinoma 12 (13.0%)
• Signet ring cell adenocarcinoma 1 (1.1%)
Tumor differentiation
• Well differentiated 22 (23.9%)
• Moderately differentiated 46 (50.0%)
• Poorly differentiated 12 (13.0%)
TNM stage
• I 8 (8.7%)
• II 22 (23.9%)
• III 24 (26.1%)
• IV 37 (40.2%)
• Unknown 1 (1.1%)
Baseline CEA (ng/mL)
• High 33 (35.9%)
• Normal 59 (64.1%)
• Median (range) 3 (0–13.318)
TNM: Tumor, Node and Metastases; CEA: carcinoembryonic antigen.
Estevez-Garcia et al. BMC Cancer 2012, 12:514 Page 4 of 10
http://www.biomedcentral.com/1471-2407/12/514underwent primary tumor surgery with curative intent.
Adjuvant fluoropyrimidine-based chemotherapy with or
without oxaliplatin was indicated in patients with high
risk stage II or stage III CRC following surgical resec-
tion. Neoadjuvant or adjuvant radiotherapy was added in
stage II-III patients with rectum primaries. Patients with
advanced stage IV disease were managed primarily with
systemic chemotherapy that included oxaliplatin- (44%)
or irinotecan-based (13%) combination regimens or
fluoropyrimidines alone (3%). With a median follow-up
of 31 months (range: 8 to 99 months), 59 patients (64%)
had died due to disease progression or to complications
of cancer therapy.
Statistical analysis
A minimum sample size of 80 patients was planned to be
screened in case no mutations were to be encountered, asin such a case the probability of finding mutations in the
general population was estimated to be very low (≤ 4.4%;
α=0.05, β=0.80) and therefore non-clinically relevant.
Considering an expected drop-out rate of about 10%
(technical issues or others), 92 patients were finally
selected for study entry. Descriptive statistics were used
to characterize the most relevant clinical parameters. The
association of categorical clinical or pathological features
and mutation type was explored by the chi-squared test
or Fisher’s exact test when appropriate. Overall survival
(OS) was calculated from the time of histological diagno-
sis to the date of death (deaths due to surgical complica-
tions were censored). The Kaplan-Meier product limit
method [19] was used to estimate OS, and differences
observed among patient subgroups were assessed by the
log rank test [20]. Multivariate analysis using the Cox
proportional hazards model [21] was performed to assess
the association between mutations and clinical outcome
while adjusting for other potential confounding factors
such as age, tumor stage, primary tumor location, CEA
levels and tumor differentiation. P<0.05 was considered
significant. All analyses were performed using the Statis-
tical Package for the Social Sciences software (SPSS 16.0
for Windows; SPSS Inc, Chicago, IL).
Results
Characterization of VEGFR2, PDGFRα and PDGFRβ
genetic variants
Three genetic variations were identified in PDGFRα
(exons 12, 13 and 17) and one in PDGFRβ (exon 19)
with respect to the registered wild type (WT) reference
sequence (NM006206 and NM002609, respectively),
whereas no VEGFR2 mutations were detected. Those
encountered in exons A12, A13 and B19 were silent
mutations showing nucleotide substitution in the third
base of the codon without modifying the codified ami-
noacide, while the one detected in A17 was an intronic
insertion. All of them corresponded to single nucleotide
polymorphisms (SNP) previously described in public data-
bases with reference SNP IDs rs1873778, rs10028020,
rs246395 and rs2412559, respectively (Additional file 1:
Table S3).
SNPs identified in CRC cell lines
Both SNP A12 and SNP A17 were found in homozygosis
in all CRC cell lines. PDGFR-A13 SNP was present in
heterozygosis in two cell lines (LS174T and LS180), and
PDGFR-B19 presented a SNP in heterozygosis in four of
them (LS174T, LS180, SW48 and SW480).
SNPs identified in CRC patient tumor samples
PDGFR-A12 and PDGFR-A17 analysis was feasible in
all tumor samples, and all of them showed the SNPs
variants in homozygosis. PDGFR-A13 was successfully
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heterozygosis in 18% of analyzed samples (13 patients).
PDGFR-B19 complete analysis was achieved in 78 patients
(85%), and the SNP B19 was found in 58% of evaluable
samples (45 patients), both in homo- and heterozygosis
(7 and 38 patients, respectively). Figure 1 illustrates DNA
sequencing of PDGFRα exon 12 and PDGFRβ exon 19,
showing SNPs identified in our population.
Correlation of PDGFRα and PDGFRβ genetic variants
and clinicopathological features
Distribution of SNPs A13 and B19 according to gender,
age, baseline CEA levels, primary tumor location, histo-
logical type, TNM stage at diagnosis and tumor differen-
tiation is described in Table 2. The only observed
correlations that were of borderline statistical signifi-
cance were those found between SNP B19 and primary
tumor location, and SNP A13 and tumor differentiation.
Indeed, the PDGFR B19 SNP was more commonly
encountered among patients with colon primaries than
in those with primary tumors located in the rectum
(63.9% vs 35.3%; p=0.051). On the other hand, PDGFR
SNP A13 was never detected in well differentiated
tumors, whereas it was identified in 23% of moderately
or poorly differentiated ones (p=0.053).
PDGFRα and PDGFRβ genetic variants and colon
cancer survival
Overall survival of patients according to PDGFR-A13
and -B19 SNPs identified is depicted in Table 3. No
significant impact in overall survival was observed forFigure 1 Electropherogram of a PDGFR sequence. 1a: Three examples
PDGFRβ exon wild type (Adenine), and SNP B19 in heterozygosis and hom
paraffin-embedded tumour tissue sample presenting PDGFRα exon 13 SNPSNP A13. On the contrary, 5-year survival of patients
PDGFR-B19 WT was substantially greater than that
observed in those harboring the SNP (51% vs 17%;
p=0.073) (Figure 2). Multivariate analyses showed the
presence of the B19 SNP variant was a significant inde-
pendent predictor of survival (HR 2.89, p=0.029). Other
variable that retained independent prognostic value in
the Cox regression model was TNM stage (p<0.001),
and age was of borderline significance (p=0.060)
(Additional file 1: Table S4).
Effect of B19 SNP in PDGF receptor levels
To explore the potential biological relevance of the iden-
tified PDGFR-B19 SNP, we assessed PDGFRβ protein
levels in each cell line and correlated them with whether
or not they harbored the SNP of interest. Of note, the
cell lines that contained the B19 SNP in heterozygosis
(LS174T, LS180, SW48 and Colo205) showed higher
levels of PDGFRβ protein than those harboring only the
wild type allele (Figure 3). In addition, these higher levels
of receptor were associated with higher levels of
Tyr1021-phosphorylated receptor (Figure 3), indicating
its constitutive activation and increased signaling of
the pathway.
Discussion
The present study evaluated the incidence of VEGFR2,
PDGFRα and PDGFRβ TK domain genetic variants in
different CRC cell lines (T84, LOVO, LS174T, HT29,
LS180, SW48, SW480, COLO205) and in tumor samples
of 92 patients diagnosed of colorectal adenocarcinoma.of paraffin-embedded tumour tissue DNA sequence analysis of
ozygosis (A to G transition), respectively. 1b: DNA sequence of a
in heterozygosis (G to A transition).
Table 2 Correlation of PDGFR A13 and B19 mutational status and clinical-pathological features
Clinical features PDGFRα exon 13 PDGFRβ exon 19
WT N (%) SNP N (%) p WT N (%) SNP N (%) p
Gender 0.754 0.346
• Female 24 (85.7) 4 (14.3) 10 (34.5) 19 (65.5)
• Male 36 (80.0) 9 (20.0) 23 (46.9) 26 (53.1)
Age 0.127 0.653
• ≤ 68-years old (median) 34 (89.5) 4 (10.5) 18 (45.0) 22 (55.0)
• > 68-years old (median) 26 (74.3) 9 (25.7) 15 (39.5) 23 (60.5)
CEA (carcinoembryonic antigen) 1.000 0.813
• Within normal range 39 (83.0) 8 (17.0) 21 (41.2) 30 (58.8)
• ≥ ULN (5 ng/ml) 21 (80.8) 5 (19.2) 12 (44.4) 15 (55.6)
Primary tumour location 1.000 0.051
• Colon 47 (82.5) 10 (17.5) 22 (36.1) 39 (63.9)
Rectum 13 (81.3) 3 (18.8) 11 (64.7) 6 (35.3)
Tumour histology 0.401 0.221
• Conventional adenocarcinoma 52 (83.9) 10 (16.1) 30 (45.5) 36 (54.5)
• Mucinous or colloid adenocarcinoma 8 (72.7) 3 (27.3) 3 (25.0) 9 (75.0)
TNM stage 0.196 0.170
• I-II 23 (92.0) 2 (8.0) 8 (30.8) 18 (69.2)
• III-IV 37 (78.7) 10 (21.3) 24 (47.1) 27 (52.9)
Tumour differentiation 0.053 0.586
• Well differentiated 15 (100) 0 (0.0) 7 (36.8) 12 (63.3)
• Moderately or poorly differentiated 37 (77.1) 11 (22.9) 23 (47.9) 25 (52.1)
Surgery of primary tumor 0.578 0.389
• Yes 55 (80.9) 13 (19.1) 32 (43.8) 41 (56.2)
• No 5 (100.0) 0 (0.0) 1 (20.0) 4 (80.0)
Surgery of metastasis 0.953 0.451
• Yes 13 (86.7) 2 (13.3) 9 (50.0) 9 (50.0)
• No 47 (81.0) 11 (19.0) 24 (40.0) 24 (40.0)
Adjuvant chemotherapy 0.295 0.986
• Yes 28 (87.5) 4 (12.5) 14 (42.4) 19 (57.6)
• No 32 (78.0) 9 (22.0) 19 (42.2) 26 (57.8)
Chemotherapy for advanced disease 0.683 0.929
• Yes 36 (83.7) 7 (16.3) 18 (41.9) 25 (58.1)
• No 24 (80.0) 6 (20.0) 15 (42.9) 20 (57.1)
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(A12): c.1701A>G, rs1873778; exon 13 (A13): c.1809G>A,
rs10028020; and exon 17 (A17): c.2439+58C>A,
rs2412559] and one in PDGFRβ [exon 19 (B19):
c.2601A>G, rs246395]. SNP B19, present in 4 CRC cell
lines (LS174T, LS180, SW48, COLO205) and in 58%
of patients, had a substantial impact on overall survival,
with 5-year survival rates of 51% for patients with PDGFR
B19 wild type tumors versus 17% for those harboring
the SNP variant (c.2601A>G). This is the first study
to analyze the PDGFR genotype in a series of human
colorectal cancer and its correlation with differentclinicopathological features, and to demonstrate a signifi-
cant association of a PDGFR SNP with patients’ outcome.
Angiogenesis is a complex process controlled by a
number of interconnected signaling pathways, among
which PDGF and their receptors play a critical role.
Moreover, PDGFR has been the target for many newly
developed anticancer drugs, some of them with proven
efficacy in CRC (i.e. regorafenib) [7] and some that have
failed to demonstrate a benefit in patients with this
tumor type (i.e. sunitinib, sorafenib) [16,17]. Despite this,
however, only few studies have analyzed the clinical
implications of PDGF/PDGFR expression in colorectal
Table 3 Overall survival according to PDGFRα and
PDGFRβ mutational status
Mutational status Patients
N (%)
Overall survival
Median
(months)
% at 5y HR P
PDGFR-A13
• WT (AA) 60 (82%) 37.1 14% 0.96 0.934
• SNP (AG) 13 (18%) 21.7 41%
PDGFR-B19
• WT (AA) 33 (42%) NR 51% 1.93 0.073
• SNP (AG,GG) 45 (58%) 37.1 17%
WT: wild type; SNP: single nucleotide polymorphism; N: number; 5y: 5 years;
HR: hazard ratio; NR: not reached.
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specific receptor tyrosine kinases (TK) were overex-
pressed in K-ras mutated CRC [22]. In particular,
VEGFR1, VEGFR2 and PDGFRα expression, documen-
ted in 95%, 46% and 62% of tested samples, respectively,
were significantly linked to K-ras codon 12 or 13 muta-
tions. Whether this could translate into a higher likeli-
hood of responding to TK inhibitors, however, is a
matter of speculation. On the other hand, Wheler et al.
reported, in a series of 99 human colorectal carcinomas,
that co-expression of PDGFRα/β, observed in 57% of
tumor samples, was significantly associated with lymph-
atic metastasis (P=0.007) and advanced tumor stage
(P=0.03) [23]. Similarly, high PDGFRβ tumor stromal
expression significantly correlated with more aggressive
clinical behavior in patients with breast cancer, including
high histopathological grade, estrogen receptor negativ-
ity, high HER2 expression and shorter survival [24].
Nevertheless, PDGFR genetic variants had never been
previously assessed in CRC patients. In our study, four
genetic variants were identified, all of them correspond-
ing to SNPs previously reported in public databases.Time (months)
12096724824
Cu
m
ul
at
iv
e 
Su
rv
iv
al
1,0
0,8
0,6
0,4
0,2
0,0
SNP-censored
WT-censored
SNP
WT
PDGFR B19
HR=1.93
P=0.073
Overall Survival by PDGFRβ exon 19 Genotype
Figure 2 Overall survival of CRC patients by PDGFRβ exon 19
genotype (WT [AA] vs SNP [GA or GG]).Three of them were silent mutations (A12, A13 and
B19) and the other one was an intronic insertion (A17).
PDGFRα exon 12 SNP (rs1873778), present in homo-
zygosis in all CRC cell lines and 100% of analyzed tumor
samples, has been also described in other neoplasias
although in a smaller proportion of patients, including
KIT and FLT3 mutation-negative core binding factor
(CBFL) acute myeloid leukemias (14% of 35 patients)
[25], cervical adenosquamous carcinomas (30% of
30 patients) [26] and gliomas (7% of 86 patients) [27]. In
this last study, no association was found between the
presence of this mutation and PDGFRα tissue expres-
sion. Our results are in agreement with the distribution
reported for a European Caucasian population at the
NCBI website (http://www.ncbi.nlm.nih.gov/sites/entrez/),
being the G-allele the most frequently encountered
(p=0.98). PDGFRα exon 13 SNP (rs10028020), detected in
heterozygosis in 2 (LS174T and LS180) of the 8 cell
lines examined and in 18% of tumor samples, was
associated with poorer tumor differentiation but no
significant correlation was found with survival. This
polymorphism had been first reported also in heterozygo-
sis by Trojani et al. in 34% of CBFL acute leukemias [25],
although potential association of this genotype with clin-
ical features or patient0s outcome was not explored by
these authors. Finally, neither PDGFRα exon 17 SNP
(rs2412559), identified in all of our patients, nor PDGFRβ
exon 19 SNP (rs246395), present in 58% of them, had
been previously described in human cancers. PDGFR B19
SNP has been reported to be present in the general popu-
lation with a frequency of 37%, and was more commonly
encountered in our study population among colon pri-
mary tumors (64%) than in tumors of rectal origin (35%).
Of note, and despite not being an activating mutation, the
B19 SNP was found to be a significant prognostic factor
(HR: 2.89, p=0.029) independent of tumor stage or
patient0s age. This negative effect on patient0s survival did
not differ according to primary tumor location (data not
shown).
That the identified SNP in exon 19 of PDGFRβ may
indeed have relevant biological implications is further
supported by the fact that analysis of protein content in
cell lines demonstrated the presence of the B19 SNP
clearly correlated with higher protein levels of the PDGF
receptor β, also in its phosphorylated state. PDGF path-
way constitutive activation maintains highly active MEK,
thus phosphorylating Bad and inhibiting apoptosis
[14,15]. Increased PDGF pathway activation has been
also shown to contribute to drug resistance by activating
the PI3K pathway [14,15]. Whether or not the presence
of this SNP may portend particular sensitivity to
PDGFR-targeted agents is a matter of speculation but
certainly deserves further investigation due to its rele-
vant potential clinical applications.
Figure 3 PDGFRβ protein expression in colon cancer cell lines. Cell lines that contained the B19 SNP in heterozygosis (LS174T, LS180, SW48
and Colo205) showed higher protein levels of PDGFRβ and p-PDGFRβ.
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our series regarding VEGFR2 TK domain SNP analysis.
As in other solid tumors, overexpression of VEGF mRNA
and protein has been associated with tumor progression
and poor prognosis of colon carcinoma [28]. The VEGF-A
gene is known to be highly polymorphic and harbors
numerous SNPs, especially in the promoter, 5’- and 3’-
untranslated regions (UTR), which contain key regulatory
elements that are sensitive to hypoxia [29]. These SNPs
contribute to the high variability in VEGF production
among tissues and have been associated with cancer
susceptibility, progression, and anti-VEGF therapeutic
response in subjects with a variety of solid tumors includ-
ing colorectal cancer. For example, the 936 T-allele has
been associated with increased risk of CRC, advanced
stage of disease and worse prognosis, whereas the 634 C
allele was predictive of decreased risk and improved sur-
vival. SNPs have also been identified in the VEGF receptor
genes, although the literature in this topic is still very
sparse. Very recently, the VEGFR-1 319 C/A SNP, located
in the promoter region of the gene, has been reported to
be associated with response to therapy in a cohort of
218 CRC patients treated with different bevacizumab-
containing regimens [30]. In this study by Hansen et al.,
response rates were significantly higher in patients
homozygous for the A-allele (AA) than in patients with the
C-allele genotype (CC or CA) (56% vs 39%, p=0.015). Simi-
lar results were also documented in bevacizumab-treated
pancreatic cancer patients [31]. In addition, functional
relevance has been demonstrated for several SNPs in the
VEGFR-1 and VEGFR-2 genes, particularly SNPs 1192C/T
(V2971I; rs2305948) and 1719T/A (H472Q; rs1870377).
These SNPs are located in exons 7 and 11, and lead to
amino acid changes potentially interfering with the recep-
tor’s binding affinity to VEGF-A. In the current study,
however, we aimed to explore potential genetic variations
in the TK domain of the VEGFR-2 (exons 17 to 26), which
would be expected to have relevant functional conse-
quences. No mutations were however detected in our
study population in these gene domains.Identification of relevant SNPs in critical genes involved
in angiogenesis may therefore become valuable tools in
assessing risk or predicting cancer response to therapy or
prognosis. However, no consensus exists at present
regarding the use of any of these for clinical decisions as
many studies have reported diverging, conflicting or in-
conclusive results. Multiple reasons may be responsible
for these discrepancies, including gender and interethnic
differences in the distribution of alleles, heterogeneous
study populations and small sample sizes, different
sources of DNA (i.e., tumor vs germline) and different
methods for SNP analyses, lack of corrections for multiple
testing, links to other loci in the gene or related genes re-
sponsible for the observed effect, bias due to post-
transcriptional gene regulation, or simultaneous presence
of somatic or epigenetic changes that may influence out-
come. Prospective validation in appropriately sized and
controlled studies is therefore required before these gen-
etic variants may be used in clinical practice.
Conclusion
In conclusion, the present study has identified, for the
first time, PDGFRβ genetic variants with relevant clinical
and biological implications. In particular, the G-allele
genotype of PDGFRβ exon 19 SNP (rs246395), which
was commonly encountered in our series of CRC
patients (58%), was associated with increased pathway
activation and poorer survival. Further studies to assess
the functional consequences of this genetic variant, as
well as to validate its role as a prognostic marker in this
disease are certainly warranted. Implications regarding
its potential influence in response to PDGFR-targeted
agents remain to be elucidated.
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